Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis.
- 1Infectious Disease Clinic, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, Lübeck, Germany.
- 2Department of Neurology, University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany.
- 3Department of Neurology, University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. [email protected].
Abstract
Introduction
Progessive multifocal leukoencephalopathy (PML) is a complication of immunoincompetence due to disease or immunosuppressive therapy and in particular due to disease modifying therapy (DMT) in multiple sclerosis. It is not clear however, whether there is a specific vulnerability to PML or whether this is due to immunosuppression per se. The same holds for the combination of cryptococcal disease and Fingolimod.Methods
We used the reporting odds ratio (ROR) as calculated from entries to Vigibase for a sample of drugs used for DMT (Alemtuzumab, Cladribine, Fingolimod, Dimethyl fumarate, Glatirameracetat, Interferon beta-1a, Interferon beta-1b, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon-beta-1a, Ponesimod, Siponimod, and Teriflunomide) and infections with the varicella zoster virus (VZV), PML, and cryptococcal and pneumococcal disease as a surrogate for the frequency of these events. Principal component analysis was used to identify outliers of the general relation between the RORs for the 4 infections studied. A plot of log(ROR) for the other infections as a function of log(ROR) of VZV infections was used to characterize the outliers more clearly.Results
The associations of PML/Natalizumab and Cryptococcal disease/Fingolimod were reported significantly more frequently than expected from the general reporting pattern as extracted from the PCA. They were the only combinations which were outside the confidence intervals of the otherwise linear correlations of log(ROR) with log(ROR) for VZV.Conclusion
These associations are candidates for which specific effects of Natalizumab and Fingolimod should be identified that increase vulnerability to respective infections.
Related
- Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug–Interaction Analysis of the FDA Adverse Event Reporting System
- Transition from extended to single-dose antibiotic prophylaxis was not associated with increased postoperative infectious complications in urologic surgery
- Gentamicin-Augmented Intrarenal Irrigation During Percutaneous Nephrolithotomy Reduces 30-Day Infectious Complications and Eliminates Pyelonephritis and Sepsis: A 1:2 Matched Cohort Study
- Syndrome-oriented CNS infectious complications after hematopoietic stem-cell transplantation and CAR T-cell therapy, part 1—viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT
- Impact of malnutrition and nutritional support on infectious complications in critically ill infants and children
BibTeX
@article{kadgien2026proportionate,
title = {{Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis.}},
author = {Frederike Kadgien and Katja Hummel and Peter Trillenberg},
journal = {Neurological research and practice},
year = {2026},
month = oct,
doi = {10.1186/s42466-026-00544-x},
url = {https://europepmc.org/article/MED/42907929},
note = {CC BY},
}
RIS
TY - JOUR
TI - Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis.
AU - Frederike Kadgien
AU - Katja Hummel
AU - Peter Trillenberg
PY - 2026
DA - 2026/10/21
JO - Neurological research and practice
DO - 10.1186/s42466-026-00544-x
UR - https://europepmc.org/article/MED/42907929
AB - Introduction Progessive multifocal leukoencephalopathy (PML) is a complication of immunoincompetence due to disease or immunosuppressive therapy and in particular due to disease modifying therapy (DMT) in multiple sclerosis. It is not clear however, whether there is a specific vulnerability to PML or whether this is due to immunosuppression per se. The same holds for the combination of cryptococcal disease and Fingolimod.Methods We used the reporting odds ratio (ROR) as calculated from entries to Vigibase for a sample of drugs used for DMT (Alemtuzumab, Cladribine, Fingolimod, Dimethyl fumarate, Glatirameracetat, Interferon beta-1a, Interferon beta-1b, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon-beta-1a, Ponesimod, Siponimod, and Teriflunomide) and infections with the varicella zoster virus (VZV), PML, and cryptococcal and pneumococcal disease as a surrogate for the frequency of these events. Principal component analysis was used to identify outliers of the general relation between the RORs for the 4 infections studied. A plot of log(ROR) for the other infections as a function of log(ROR) of VZV infections was used to characterize the outliers more clearly.Results The associations of PML/Natalizumab and Cryptococcal disease/Fingolimod were reported significantly more frequently than expected from the general reporting pattern as extracted from the PCA. They were the only combinations which were outside the confidence intervals of the otherwise linear correlations of log(ROR) with log(ROR) for VZV.Conclusion These associations are candidates for which specific effects of Natalizumab and Fingolimod should be identified that increase vulnerability to respective infections.
SN - 2524-3489
ER -